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ABSTRACT 
Viral bacterial coinfections are known to cause severe pneumonia, especially in the 
elderly and in pediatric patients. Antibiotics like β-Lactams kill the bacteria but fail to 
improve symptoms suggesting a faulty immune system may play an important role in the 
disease. Interleukin-1β (IL-1β) is an important immune signaling cytokine responsible for 
inflammation. It exists as an inactive precursor that can be activated by caspase-1 
containing inflammasomes (multi-protein complex). Influenza A virus (IAV) and 
Streptococcus pneumoniae (S. pneumoniae) activate the inflammasome through the 
NOD-like receptor protein NLRP3 and/or AIM2. Previous reports in mice indicate that 
IL-1β levels are dramatically elevated during coinfection with IAV and S. pneumoniae. 
However, how IL-1β levels increase and their importance in coinfection is not known. 
We have discovered that IL-1β expression and secretion is increased during coinfection 
as a result of activation of multiple signaling pathways simultaneously. This was 
concluded in experiments where macrophages or mice deficient in various immune 
pathways including Myd88, Aim2 or Nlrp3 genes were examined for their effects on IL-
1β production. Treatment options were then explored. Mice were given an antibiotic 
and/or an IL-1β neutralizing antibody. Treatment of mice with clindamycin antibiotic 
significantly improved mortality and simultaneously reduced IL-1β levels. Further 
inhibition of IL-1β using neutralizing antibodies resulted in improved weight gain 
compared to clindamycin alone. Thus, we concluded that IL-1β plays an important role 
during the coinfection of IAV and S. pneumoniae. 
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 1 
INTRODUCTION 
 
 
A coinfection occurs when the host is infected by one pathogen, which initiates an 
immune response and taxes the body’s resources. A second pathogen then takes 
advantage of this weakness and also attacks the host (1). Secondary bacterial infection 
during influenza A virus (IAV) infection is a contributing factor to disease severity and 
mortality. Streptococcus pneumoniae (S. pneumoniae) is one of the main pathogens 
causing coinfection following IAV infection (2-4). In fact, the coinfection of IAV and S. 
pneumoniae is the 8th leading cause of death in the United States (5). Throughout history, 
influenza pandemics have taken millions of lives. The highest mortality was recorded in 
the 1918-1919 H1N1 “Spanish flu” pandemic, which resulted in 50-100 million deaths 
(6-8). Autopsies of Spanish flu victims linked the deaths to severe complications related 
to bacterial coinfections, with S. pneumoniae as a major coinfecting agent (9-12). 
Subsequent research has shown that infection with more severe IAV strains leads to 
increased susceptibility to bacterial coinfections (8, 13, 14). In this particular coinfection, 
the immune system response plays an important role in the development of disease. In 
part, the response of the immune system to IAV is different than the one to S. 
pneumoniae. Thus, when a coinfection occurs, the immune response to IAV impairs the 
response to S. pneumoniae. Therefore, to understand coinfection, one must first 
understand the pathogens involved and the immune response to those pathogens. Our 
hope is that a better understanding of the mechanisms responsible for this coinfection can 
facilitate the quality of treatment available. 
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Influenza A Virus 
IAV is an enveloped negative-sense single-stranded RNA virus part of the 
Orthomyxoviridae family (15). Its genome is made up of eight RNA segments that can 
encode up to 12 different proteins. There are two types of glycoproteins, hemagglutinin 
(HA) and neuraminidase (NA). Within those two groups, there are 17 subtypes of HA 
(H1–H17) and 9 of NA (N1-N9) (16-18).  Additional proteins include the matrix proteins 
1 and 2 (M1 and M2) (19), nucleoprotein (NP) (20), polymerase complex proteins (Phox 
and Bem1/2 ( PB1, PB2,) and Polymerase acidic protein ( PA) ) (21, 22), and non-
structural proteins 1/2  (NS1 (23), NS2 (24, 25),), PA-X (26) and PB1-F2 (27). There are 
four types of influenza viruses (A, B, C, D) (28-30). Influenza types A, B and C originate 
from avian, mammal and human sources and all three are able to cause infection in 
humans, with influenza A virus producing the most severe disease and influenza C virus 
the least severe (31-33). Influenza D virus thus far has only been detected in cattle (30). 
The influenza A virus has been seen under prevailing pandemic conditions, due to being 
the only strain with an animal reservoir that can transmit to humans, hence attention has 
mostly been focused on it (34, 35). Transmission of the virus occurs through inhalation of 
infectious air droplets and contact with infected fomites (36). Once inside the body, the 
virus infects columnar epithelial cells in the respiratory tract by the attachment of HA to 
specific sialic acid residues, which are present on the cell surface through post-
translational glycosylation modifications on cell proteins destined for the cell surface. 
Binding to sialic acid induces Clathrin mediated endocytosis (CME) or other alternative 
endocytic routes, which allows the virus to enter the cell (37, 38). Once the virus is in the 
endosome, M2 proteins allow H+ ion influx and cause dissociation of M1 proteins from 
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nucleocapsids. Viral and endosomal membrane fusion through changes in the HA protein 
conformation also occur (39). The viral ribonucleoprotein particles (vRNPs) made up of 
viral genomic RNA (vRNA), PB1, PB2, PA, and NP are released into the cytoplasm and 
translocate to the nucleus to begin replication and transcription (40, 41). When the 
vRNPs enter the nucleus, transcription of positive sense viral mRNA begins (42, 43). 
Transcription initiates when PB2 binds to the 5′-cap structure of host mRNAs, cutting it 
and snatching it to allowing those ~12 nucleotides to serve as a primer template for the 
polymerase acidic protein (PA) to start mRNA synthesis (44-46). The viral polymerase 
also produces complementary RNA (cRNA), which is similar to mRNA, but without a 
5’-cap. This cRNA is then used as a template to make the negative stranded vRNA. Once 
sufficient viral proteins have been synthesized using the mRNA, the virus polymerase 
switches to the production of vRNA. vRNA exits the nucleus and M1 proteins package 
the virus so it can be ready to exit the cell (47). Newly packed virions then assemble at 
the plasma membrane and initiate a process called budding (48). First, HA and NA 
interact with lipid rafts (cholesterol enriched regions) in the plasma membrane allowing 
the initiation of budding. Second, M1 protein is recruited and binds to the cytoplasmic 
tails of HA an NA. Then vRNPs gather around the M1 protein. Third, virion elongation 
occurs due to the polymerization of the M1 protein. Budding is finalized when the M1 
protein recruits the M2 protein, which initiates membrane scission and viral release. 
Finally, when the virus buds out of the cell, NA protein allows it to detach from sialic 
acid receptors and infect new cells (49, 50) . IAV causes the disease influenza, with 
symptoms consisting of fatigue, runny nose, fever, chills, headaches, muscle aches, and 
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congestion. IAV also allows bacteria like S. pneumoniae to initiate pathogenicity through 
multiple factors (51-55). 
 
Streptococcus pneumoniae (S. pneumoniae) 
S. pneumoniae is a non-spore forming diploccoci, characterized by its round two-
joined cells that can form long chains. It is facultative anaerobic, being able to grow with 
or without oxygen. It is also alpha-hemolytic, so when grown on a blood agar plate, it 
oxidizes hemoglobin and lyses red blood cells. This type of hemolysis results in a green 
zone being produced around bacterial colonies. This bacterium is transformable, being 
able to take up genetic material from the environment.  It is also nutritionally fastidious, 
needing specific nutrients and environmental conditions to grow. Finally, it also ferments 
lactic acid (56, 57). Its mode of transmission consists of droplets or aerosols distributed 
between hosts (58). Exposure of the host is followed by nasopharyngeal epithelial cell 
attachment made possible by mucosal evasion due to its capsule and neuraminidase 
(NanA). This leads to asymptomatic colonization in some people but systemic 
dissemination in others (59). This colonization is mainly found in the nasopharynx of 
children, yet the carriage rate decreases with age (60, 61). 
 S. pneumoniae is a gram-positive bacteria, and its cell wall consists of 
peptidoglycan and teichoic acids. A polysaccharide capsule covers the cell wall. S. 
pneumoniae virulence can be categorized by serotyping its capsular polysaccharide (62). 
Some serotypes act as primary pathogens and easily invade the host, yet higher mortality 
rates are related to opportunistic pathogens containing serotypes with lower invasive 
disease potential such as S. pneumoniae type 3 strain. The polysaccharide capsule 
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contains a unique teichoic acid component: a ribitol phosphate backbone that binds to 
phosphorylcholine (PCho) (63). PCho facilitates bacterial endocytosis, entrance into the 
bloodstream and crossing of other barriers due to its interaction with the platelet-
activating factor receptor (PAFr) present on human cells (64). It also has pili, which aid 
with adhesion to human cells. Pneumococcal surface protein A (PspA), and choline 
binding protein (Cpb) A also aid in adherence (57). Adherence to the alveolar epithelium 
and the release of toxic components such as the exotoxin pneumolysin (PLY) and 
hydrogen peroxide results in alveolar damage and fluid build-up in the alveolar space (65, 
66). PLY is a toxin produced by S.pneumoniae responsible for damaging the host’s 
membrane by forming lytic pores. It has also been shown to cause DNA- double strand 
breaks resulting in cell cycle arrest (67). Hydrogen peroxide has been shown to be 
produced by S. pneumoniae in aerobic conditions through a pyruvate oxidase. It harms 
alveolar epithelial cells and other bacteria that share a common microenvironment (68).  
Although S. pneumoniae is an extracellular pathogen that can asymptomatically 
colonize the upper respiratory tract, when the body is weakened, an opportunistic 
pathogen such as S. pneumoniae is able to become invasive and cause disease. S. 
pneumoniae can cause pneumonia, which is characterized by alveolar inflammation 
usually centering in one lobe of the lungs (69). Some of the symptoms linked to 
pneumonia are chills, fever, cough with phlegm or pus, and difficulty breathing. In 
addition to pneumonia, this pathogen is associated with otitis media, meningitis and 
septicemia (13, 70). These conditions are especially prominent following IAV infection 
and can cause the immune system to over react (13, 70).  
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The Immune System and Inflammation 
The immune system is responsible for orchestrating cells, tissues, and organs to 
maintain homeostasis and defend the body against foreign agents. Inflammation is a 
biological response to harmful stimuli. It is characterized by five hallmarks: redness, 
increased heat, swelling, pain and loss of function. These five signs are due to 
vasodilation, increased vascular permeability, decrease cell function and increased 
vascularity (71). Inflammation allows the immune cells to communicate and migrate to 
the site of trauma. Unfortunately, if the immune system is not properly regulated, 
inflammation can get out of control. This can be due to intrinsic factors like genetic 
mutations or extrinsic factors such as coinfections (72, 73). Inflammation is initiated and 
regulated by the two arms of immunity: innate and adaptive.  
Innate immunity is the first line of defense. If a piece of broken glass punctures 
the skin, the innate immune system will coordinate immune cells such as macrophages, 
neutrophils, eosinophils, basophils, dendritic cells and natural killer cells to arrive at the 
site of trauma. Macrophages are mature monocytes that patrol the vasculature and reside 
in tissues with the main purpose of recognizing foreign particles. They are antigen 
presenting cells (APCs) meaning that they travel to lymph nodes and show antigens to T 
cells and B cells resulting in their activation. Most resident macrophages are 
embryonically derived, yet others originate from hematopoietic stem cells (HSC) in the 
bone marrow (74). Neutrophils originate from HSC, and travel to the site of infection and 
produce toxic substances such as hydrogen peroxide and superoxide, and form neutrophil 
extracellular traps (NETs) to eliminate foreign particles. Dendritic cells are also APCs; 
they travel to the site of infection to gather information about the foreign agent and then 
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travel to the lymph nodes to present the antigen to adaptive immune cells. The innate 
immune system also contains a group of proteins that make up the complement system. 
These proteins help with pathogen recognition by attaching to the foreign agent. They 
also surround the agent and impede its movement to other areas by a process called 
opsonization. Finally, they  eliminate the foreign agent by inducing cell lysis via the 
membrane attack complex (75).  
Specific immune receptors called Pattern Recognition Receptors (PRRs) present 
on epithelial and immune cells can detect Pathogen Associated Molecular Patterns 
(PAMPS), like bacterial peptidoglycan or viral RNA, or damage-associated molecular 
patterns (DAMPs), like membrane damage caused by S. pneumoniae PLY and changes in 
ion concentration occurring during infection. These PAMPS and DAMPS activate PRRs 
to initiate immune signaling cascades (76, 77). All together, these cells initiate signal 
transduction pathways that result in transcriptional enhancement of immune system 
genes, inflammasome (multiprotein complex) activation and cytokine (immune signaling 
molecules) production with the final goal of pathogen elimination and return to 
homeostasis. Overall, the innate immune system has a major role in controlling 
inflammation (78).   
Adaptive immunity is a long-term type of immunity, it takes a few days to form, 
yet long-lasting memory helps protect the body from future attacks. It is made up of the 
humoral and cellular immune responses. The humoral response consists of B 
lymphocytes that will produce antibodies to protect the body from future infections. The 
cellular response consists of T lymphocytes that will further help with the elimination of 
pathogens through receptor specificity. In the adaptive immune system, cells present 
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specific components from foreign particles called antigens to the receptors located on T 
and B lymphocytes. This antigen presentation results in the activation, migration, and 
differentiation of cells (79). During coinfection, the adaptive immune response to IAV 
results in the production of specific cytokines like Interferon (IFN)-  that can affect the 
innate immune response to the secondary infection with S. pneumoniae (80). 
 
Inflammation and Immunity During Coinfection 
The coinfection of IAV and S. pneumoniae results in pneumonia due to multiple 
factors. The cooperation between coinfecting pathogens causes severe pneumonia due to 
enhanced pathogen growth and dissemination as well as enhanced inflammation (81). 
IAV and S. pneumoniae work in a synergistic manner to increase activation of PRRs 
resulting in enhanced immune signaling production and inflammation.  
Since the immune response to coinfection plays an important function in the 
pathology of this disease, it is important to have a better understanding of the causes of 
inflammation. The immune response begins when IAV initiates an infection. Then, the 
virus limits some immunological mechanisms allowing S. pneumoniae to leave its normal 
microenvironment in the pharynx and infect the lungs. If we look at this in greater detail, 
the virus infects the host and spreads, causing the immune system to start trying to 
eliminate it. Infected lung epithelial cells attract alveolar macrophages and monocytes 
from the peripheral blood, so they can begin viral clearance through phagocytosis of 
infected cells (82, 83). This intercommunication occurs through the receptor interaction 
of the chemokine (C-C motif) ligand 2 (CCL2) and C-C chemokine receptor type 2 
(CCR2) (84). Other cells like Natural Killer (NK) cells aid in IAV elimination through 
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sialylated NK Cell Activating Receptors (NKp44/ NKp46) – HA interaction (85). 
Another cell type involved in the IAV immune response are dendritic cells. They can 
detect IAV viral particles and mature in response to inflammatory signals. They can also 
become infected by the virus or phagocytose the virus and express the viral antigens on 
their cell surface through a group of proteins called Major Histocompatibility Complex 
(MHC). Dendritic cells then migrate from the lungs to the lymph nodes. At the lymph 
nodes, they present IAV antigens to T and B cells, which results in T cell activation or 
antibody production. MHC I can activate cluster of differentiation (CD) 8+ cytotoxic T 
cells  (CTL) (86) and MHC II is able to activate CD4+ helper T cells and B cells (87). 
Antibodies produced by B cells against viral proteins HA(88), NA(89), M2(90) and 
NP(91) aid in viral clearance. T cells also play a major role in the IAV immune response. 
CD8+ cytotoxic T cells recognize and eliminate virus infected cells (92). To highlight 
their importance, viral clearance is delayed if these cells are not present. Naïve CD4+ T 
cells can differentiate into T helper 1 cells ( Th1) when a viral infection is detected. 
These cells secrete cytokines (IFN-γ, Interleukin-2 (IL-2), and Tumor Necrosis Factor-α 
(TNF- α), which enhance the activation of CD8+ T cells and macrophage function and 
also play a role in B cell differentiation (93). Other types of T cells are also involved. 
Regulatory T cells (Tregs) promote a well-balanced viral immune response created by 
CTL and CD4+ T cells and also help with the resolution of inflammation (94). T helper 
17 cells (Th17) counteract Tregs and enhance T helper cell viral responses (95). Overall, 
the adaptive immune response is required for the resolution of infection and protection 
from future infection, but it must be regulated appropriately. 
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Transcriptional Activation: PRRs and PAMPS. In addition to initiating an 
adaptive immune response, the pathogenic particles also trigger innate immunity. When 
PRRs present on epithelial and immune cells detect PAMPS or DAMPs created by the 
virus or the bacteria, an immune signaling cascade or activation of immune effector 
molecules is initiated (Figure 1A). Activation of PRRs during coinfection can induce 
inflammation through two mechanisms. The first is transcriptional activation of immune 
system genes. This starts by activating PRRs such as Toll-like receptors (TLRs), retinoic 
acid-inducible gene-I (RIG-I)-like receptors (RLRs), and certain Nucleotide 
oligomerization domain (NOD)-like receptors (NLRs). RLRs are cytoplasmic sensors 
that detect viruses. RIG-I is part of the RLR family and detects the 5′ triphosphate (PPP) 
of uncapped-RNA of IAV (96, 97). RIG-I deficiency has been linked to a delayed and 
attenuated antiviral response (98, 99). NLRs are another type of PRR. The NLRs have 22 
members and are subdivided into four categories: NLRA, NLRB, NLRC, and NLRP 
(100). Nucleotide oligomerization domain-2 (NOD2) is an NLR part of the NLRC 
subfamily. It becomes activated by muramyl dipeptide (MDP) of bacterial peptidoglycan, 
hence it detects the peptidoglycan of S. pneumoniae (101, 102). Mice with NOD2 
mutations have a higher susceptibility to bacterial and viral infections (103). TLRs are 
type I transmembrane proteins; there have been twelve murine and ten human TLRs 
characterized, but the most important ones when studying this coinfection are TLR2, 
TLR9, TLR3 and TLR7. TLR2 recognizes bacterial lipoprotein, lipoteichoic acids and 
lipomannans. TLR2 is important for recognizing PAMPs from gram-positive bacteria 
such as the peptidoglycan of S. pneumoniae (104, 105). Tlr2-/- mice have a difficult time 
clearing bacterial infection with S. pneumoniae primary infection, yet a difference in 
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immune response and bacterial outgrowth is not seen in post-influenza pneumococcal 
pneumonia (106-108). On the other hand, TLR9, which is embedded in an endosome 
membrane, recognizes 5'—C—phosphate—G—3' (CpG) deoxyribonucleic acid (DNA), 
present in S. pneumoniae (109). TLR3, also embedded in an endosome, detects viral 
double-stranded RNA, which is present in IAV (110). Deficiency in TLR3 in humans 
results in an increased risk of pneumonia, yet Tlr3-/- mice appear to have improved 
mortality compared to wild-type mice due to a decrease in inflammation (111-113). 
TLR7 is also embedded in an endosome and recognizes single stranded RNA from IAV 
(114-116). Tlr7-/- mice have delayed S. pneumoniae disease progression after IAV 
challenge due to decrease alveolar macrophage depletion, yet in the end, they still 
succumb to the coinfection (116). Importantly, this suggests that signaling through other 
immune receptors is important and that no single PRR may be responsible for 
inflammation during coinfection. 
Transcriptional Activation: Downstream Adaptor Proteins. After receptor 
activation, downstream adaptor proteins become stimulated. The Mitochondrial antiviral-
signaling protein (MAVS) becomes activated by RIG-I (Figure 1). Sun et al. explored the 
effect of Mavs deficiency in mice during viral infections, and found that these mice have 
difficulty fighting viral infections due to a reduction in interferon production (117).  The 
Receptor-interacting serine/threonine-protein kinase 2 (RIPK2) adaptor protein becomes 
activated when it receives signals from NOD2. Lupfer et al. found that Ripk2−/− mice are 
more susceptible to IAV infection due to defective induction of damaged induced 
degradation of the mitochondria (mitophagy). These mice also showed increased 
production of proinflammatory cytokines IL-18 and IFN-γ (118). Adaptor protein 
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Myeloid differentiation primary response gene 88 (MYD88) is an essential member of 
several signaling pathways responsible for proper immune function including TLRs and 
interleukin-1 family cytokine receptors. It has been previously shown that deficiency in 
Myd88 leads to susceptibility to infection with pyogenic bacteria like S. pneumoniae. In 
vivo, mortality, morbidity, and bacterial growth in Myd88 deficient mice were enhanced 
compared to WT mice (119, 120). In addition, mice lacking this protein cannot signal by 
using the IL-1R signaling pathways (121, 122). MYD88 protein is able to interact with 
almost all TLRs, except TLR3, which signals in a MYD88-independent pathway 
(123).TIR-domain-containing adapter-inducing interferon-β (TRIF) is another adaptor 
protein activated by some TLRs. It has been noted in murine studies that the TRIF/TLR3 
pathway is responsible for excessive inflammation leading to pulmonary edema, 
increased proinflammatory responses and mortality (124).  
Transcriptional Activation: Transcription Factors. MYD88 and/or TRIF can 
subsequently activate the transforming growth factor β-activated kinase (TAK1) (Figure 
1 B). The kinase then connects with the inhibitor of κB (IκB) kinase kinases (IKK) 
complex which results in phosphorylation of IκB and the nuclear translocation of the 
transcription factors nuclear factor kappa-light-chain-enhancer of activated B cells (NF-
κB) (125). NF-κB is a family of five transcription factors that are upstream regulated by 
adaptor proteins and PRRs (126). They can also be activated by oxidative stress and 
cytokines. Among this family of transcription factors, the dimer RelA (p65)/p50 is the 
most well-known. It resides in the cytoplasm of immune cells. The dimer is kept inactive 
by a family of IκBs (α/β/γ). For the p65/p50 dimer to become activated, the serine 
residues of the IκBs have to be phosphorylated by the IKK complex, which is triggered 
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by PRR-adaptor protein interaction. The phosphorylation of IκBs results in 
polyubiquitination (Lys21/ Lys22 )  and 26S proteasome degradation of IκBs resulting in 
nuclear translocation of the NF-κB dimers. Once in the nucleus, the dimers bind to the 
promoters of many genes through κB motif interactions. The dimer also initiates 
transcription of IκB genes as a negative feedback mechanism to prevent excessive 
inflammation (127). NF-κB is involved in many processes, hence, unregulated activation 
of it can lead to reduction of apoptosis, increased cell survival and increased 
inflammation. Although over activation of  NF-κB would produce increased 
inflammation, which would results in an enhance immune response in the lung, enhanced 
inflammation only further impairs lung function and makes pneumonia worse.  
In addition to NF-κB, other transcription factors like Interferon Stimulated gene 
factor 3 (ISGF3) and Interferon Regulatory Factor 3 or 7 (IRF3/7) play a role in 
coinfection pathogen recognition. TLR3 and RIG-I initiate a signaling cascade which 
results in the activation of IRF3/7. These transcription factors localize to the nucleus and 
initiate the transcription of Type I interferons (IFN-α/β). The interferons then signal the 
interferon-α/β receptors (IFNAR) in an autocrine/paracrine manner resulting in their 
activation (Figure 1C). After ligand recognition, the heterodimer interferon-α/β receptor 
(IFNAR) 1/2 couple with receptor-bound Janus kinases (JAK1) and tyrosine kinase 2 
(Tyk2) (128). These kinases cross phosphorylate each other which results in their 
activation. Once activated, they phosphorylate tyrosine kinases leading to recruitment and 
phosphorylation of two latent proteins called Signal transducer and activator of 
transcription (STAT) 1/2. STAT 1/2 deficiency has been linked to increased 
susceptibility to IAV and other viruses (129, 130). STAT 1 and STAT 2 interact with 
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Tyk2 followed by activation of IRF9. The complex of STAT1/2 and IRF9 translocate to 
the nucleus and form the heterotrimeric transcription factor Interferon-stimulated gene 
factor 3 (ISGF3).  
Transcriptional Activation: Cytokines. In the nucleus, NF-κB and ISGF3 
initiate transcriptional regulation of immune signaling molecules called cytokines. IFN-
α/β are cytokines that serve an important protective function against viral replication, yet 
they increase bacterial burden by decreasing neutrophil responses needed to fight off 
bacterial pathogens (131-134). Type 2 interferon, IFN-γ, production has also been linked 
to impaired alveolar macrophage function and bacterial burden after coinfection (73, 80, 
135-137). Interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α) are proinflammatory 
pyrogenic cytokines transcribed by NF-κB (138). Interleukin-1-beta (IL-1β) is another 
proinflammatory pyrogen produced by leukocytes and is a key inflammatory mediator 
that can regulate the production of TNF-α and IL-6 (139-141). IL-1β plays an important 
role in both the innate and adaptive immune response and irregularities in this cytokine 
have been linked to inflammatory disorders, tumor angiogenesis and metastasis (142). It 
is synthesized as an inactive precursor (pro-IL-1β) that must be activated by a 
multiprotein complex called the inflammasome (143). NF-κB is also in charge of the 
transcriptional regulation of the components necessary to form the inflammasome (129, 
144).  
Inflammasome Activation. There are different types of inflammasomes, yet the 
two most important ones during this coinfection are the NLR Family Pyrin Domain 
Containing 3 (NLRP3) and Absent in melanoma 2 (AIM2) inflammasomes. The NLRP3 
inflammasome is a multiprotein complex containing the NLRP3 protein, the apoptosis-
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associated speck-like protein containing a caspase recruitment domain (ASC) and the 
cysteine protease caspase-1. NLRP3 senses dsRNA from IAV (145). It also senses 
DAMPs like reactive oxygen species, and K+ and H+ fluxes resulting from cell damage 
caused by IAV or S. pneumoniae infection (143, 146-149). AIM2 can also activate the 
inflammasome when it recognizes DNA in the cytoplasm from S. pneumoniae (148, 150). 
Active caspase-1 in the inflammasome cleaves inactive pro-IL-1β into their active forms 
and triggers pyroptotic cell death. Once activated, IL-1β leaves the cell through pores and 
activates inflammation (151-153). Pro-IL-1β can also become active by Fas 
signaling/Caspase-8 and by a noncanonical inflammasome pathway involving Caspase-
11 or by extracellular cleavage by neutrophil protease 3 (154).  
 
Pathogen Immune Evasion 
Even though the immune system is complicated, pathogens such as IAV and S. 
pneumoniae have found a way to evade it. 
Influenza A Virus. IAV has certain mechanisms to evade the immune system 
(155).  NS1 inhibits the recognition of 5'-triphosphate (uncapped) viral ssRNA by innate 
receptors (156). It can also inhibit dendritic cell maturation (157). Overall, it has been 
shown that IAV can prevent monocytes from differentiating into dendritic cells by 
affecting antigen endocytosis and reducing the amount of CD11c, CD172a, CD1w2 and 
CCR5 cell surface proteins present (157). In addition, PB2 (158), PB1 (159) and PA 
(160) play a role in cap snatching, which limits innate immune receptors from 
recognizing IAV RNA and results in diminished immune signaling. IAV can also evade 
natural killer cells by replicating inside them and inducing apoptosis (161). IAV is able to 
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evade the humoral immune response due to antigenic variation, which can be categorized 
either as antigenic shift or drift. Antigenic drift occurs when the virus experiences small 
changes in its genome due to point mutations. During antigenic drift, mutations can 
accumulate preventing antibodies from recognizing the virus. Antigenic shift is the virus’ 
ability to change HA and/or NA proteins. This allows the virus to have infinite subtypes. 
It occurs when the virus jumps from one reservoir to another creating an antigenically 
distinct virus. It can also occur through re-assortment, when two viruses infect one 
reservoir simultaneously also resulting in a distinct virus through genetic recombination 
(162). During antigenic shift, the emergence of antigenically unique viruses occurs. 
Hence, antibodies have no effect on the new virus, so it takes the body a long time to 
produce the proper immune response (163, 164). A final way IAV can evade the immune 
system is by interfering with T cell recognition. This occurs when amino acid variation 
and alteration of epitope regions interferes with antigenic presentation and detection (58). 
For example, mutations in the Cytotoxic T lymphocyte (CTL) epitopes and amino acid 
substitutions in the NP aid IAV to escape from CTLs (165).  
S. pneumoniae. The innate immune system usually eliminates S. pneumoniae by 
opsonizing, phagocytizing and killing the bacteria. This is possible due to complement 
opsonizing the bacteria and neutrophil receptors interacting with the complement 
proteins. S. pneumoniae immune evasion targets this mechanism (166). Several structural 
components of S. pneumoniae aid it through immune evasion. Its polysaccharide capsule 
covers its cell wall and prevents most of the PAMPs in the cell wall from being detected 
by PRRS. This capsule is also antigenically diverse, thus preventing the production of a 
universal antibody against S. pneumoniae. The capsule also prevents the bacteria from 
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being phagocytosed by macrophages, and to be damaged by toxic substances produced 
by neutrophils. It also prevents the bacteria from getting trapped in the mucus in the 
lungs, and it impedes opsonization by complement (167). The production of proteins such 
as PspA by S. pneumoniae inhibit one of the complement pathways by competing with its 
attachment to the bacteria (168). PLY released from the bacteria also aids in immune 
evasion by shifting the focus of the complement proteins to the toxin and not to the 
bacterial itself (169). Finally, protein NanA also impedes complement deposition and 
disrupts neutrophil killing by deglycosylation of complement components (170). In 
addition to having its own protective mechanism, S. pneumoniae can benefit from IAV 
infecting the host. 
IAV Facilitates S. pneumoniae infection.  IAV facilitates the adherence of S. 
pneumoniae to airway epithelium by damaging the epithelial layers. The damage results 
in exposure of the underlying basement membrane and impairment of progenitor 
epithelial cells impeding their repair. Damage results in exposure of receptors such as 
fibrin and the platelet activating factor receptor (PAFr) (171). The pneumococcal surface 
protein A (PsaP) and pneumococcal serine-rich repeat protein (PsrP) are then able to 
interact with these receptors. In addition to exposure of receptors, the neuraminidase 
protein of IAV desialylates terminal sialic acids exposing galactosyl moieties to serve as 
ligands for galectins. Galectin 1 and 3 can then bind to the bacteria’s capsular 
polysaccharide increasing adherence to the lung tissue (172). IAV can also impede 
bacterial clearance (55, 73, 173-175). Pittet et al. compared bacterial clearance on the 
trachea of uninfected mice versus those infected with IAV. A decrease in bacterial 
clearance was seen on the mice infected with IAV. As previously stated, S. pneumoniae 
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resides in the nasal epithelium, and to reach the lungs it requires tracheal passage. IAV 
damages the cilia on the tracheal epithelium resulting in decreased tracheal mucocialiary 
velocity. This impedes the normal pneumococcal removal by movement of the mucus 
and ciliary beating and results in increased bacterial numbers that could eventually reach 
the lungs to cause pneumonia.  
Finally, IAV infection enhances bacterial growth due to the depletion of alveolar 
macrophages (73, 135, 174, 176) and dysregulation of neutrophils (177-179). Following 
the coinfection, an elevated number of neutrophils is seen. Even though the quantity of 
these cells increases, their antimicrobial ability is reduced by the lack of activity from the 
myeloperoxidase enzyme stored in their azurophilic granules. This enzyme is involved in 
inflammation and oxidative stress (180). Thus, infection with IAV facilitates the invasion 
and inhibits the removal of S. pneumoniae leading to a severe infection, pneumonia, and 
even death. 
 
Treatment 
           During coinfection, antiviral drugs can decrease complications from bacterial 
coinfections when given during the viral infection. This may prevent the initial tissue 
damage that aids S. pneumoniae superinfection (181). Previous studies show that 
treatment with β-lactam antibiotics, like ampicillin, can kill the bacteria but increase 
inflammation by the release of pneumococcal cell wall components through bacterial 
lysis (181). On the other hand, treatment with protein synthesis inhibitors that have a 
bacteriostatic effect, such as clindamycin, can improve the clearance of the bacteria 
without further stimulating the immune system via bacterial cell lysis (182). Although 
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specific cytokines play pathological roles during coinfection, the treatment of human 
patients with corticosteroids during coinfection provides no benefit (183-186). Thus, the 
global inhibition of inflammation may not be beneficial, and the specific roles of 
cytokines need to be examined to determine which have therapeutic potential. Thus, 
effective treatment of coinfection requires addressing the pathogens and immune-
mediated pathology. 
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HYPOTHESES 
 
Even though a vast amount of information is known about its regular biological 
function, the specific role played by IL-1β during the coinfection of IAV and S. 
pneumoniae has not been thoroughly studied. IL-1β plays a role in the activation of other 
pro-inflammatory cytokines such as TNF-α and IL-6 (141). These other cytokines are 
enhanced during this coinfection resulting in increased inflammation (171). Since TNF-α 
and IL-6 are enhanced during the coinfection then the production of IL-1β might be 
elevated as well. I  propose the following two hypotheses to explain the production of IL-
1β in this coinfection and the benefits that might result from its regulation:  
Hypothesis one: IL-1β production will be enhanced during the coinfection of IAV 
and S. pneumoniae in vitro in bone marrow derived macrophages and in vivo in C57Bl/6 
mice compared to its production during the single infection. 
Hypothesis two: Controlling IL-1β’s production in the C57Bl/6 mice by using 
neutralizing antibodies will help improve the immunopathology resulting from this 
coinfection. 
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METHODS 
 
 
Overall Experimental Design 
Experiments in cell culture and mice were performed to check their immune 
response to the coinfection of influenza A/PR/8/34 H1N1 virus and Type 3 S. 
pneumoniae (ATCC 6303). Cell cultures were single infected or coinfected with 
infectious virus and/or bacteria, and samples were collected to check cytokine and protein 
production as well as gene expression. Mice were infected and monitored for mortality 
and morbidity after being single infected or coinfected with virus and/or bacteria. In some 
experiments, lungs from infected mice were collected to check for cytokine production, 
immune cell infiltration and viral and bacterial titers. 
 
Mice 
Cell cultures of bone-marrow-derived-macrophages (BMDMs) were generated by 
harvesting bone marrow from tibia and femurs from WT, or Nlrp3-/-, Myd88-/-, Aim2-/-, 
Casp1-/-, Asc-/-, Tlr7-/- Tlr2-/- ,Ripk2-/-, Trif-/-, and Mavs-/- knockout mice all on the 
C57BL/6 genetic background. After bone marrow harvesting, cells were differentiated in 
L929 conditioned medium for 5 days as previously described (187). BMDMs were then 
counted and seeded in 12 well plates (Thermo Scientific, 130185) . The following day, 
BMDM were infected as described below.  
Pathogen-free C57BL/6, Nlrp3-/-, Myd88-/-, Aim2-/- mice (Mus musculus), were 
originally obtained from The Jackson Laboratory and then bread in-house. Casp1-/-,     
Asc-/-, Tlr7-/-, and Tlr2-/- knockout mice were housed at St. Jude Children’s Research 
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Hospital and have been reported previously [39, 77, 78]. CO2 asphyxiation followed by 
cervical dislocation was used to euthanize the mice. Infected mice were maintained in a 
Biosafety level 2 facility. All breeding and experiments were performed at the Missouri 
State University Vivarium in accordance with Institutional Animal Care and Use 
Committee (IACUC) guidelines under protocol (January 8, 2016; approval #16.009 and 
February 17, 2016; approval #16.015), the AVMA Guidelines on Euthanasia, NIH 
regulations (Guide for the Care and Use of Laboratory Animals), and the U.S. Animal 
Welfare Act of 1966.  
 
Preparation of Viral and Bacterial Stocks 
Viral and bacterial infectious agents were used in this study. Prior approval for 
this project was obtained from the Institutional Biosafety Committee (IBC) on October 
2nd, 2015. Highly pathogenic mouse-adapted influenza A/PR/8/34 H1N1 virus hereafter 
referred as “PR8” stocks were propagated by allantoic inoculation of hen’s eggs with 
seed virus.  Embryonated chicken eggs were obtained from Charles River Labs and 
infected with IAV at 10 days old. Allantoic fluid was collected after three days. Plaque 
assays were performed using Madin-Darby canine kidney (MDCK) cells (a gift from Dr. 
Paul Thomas, St. Jude Children’s Research Hospital) to determine stock titer. Two days 
before assay MDCK cells were seeded in 12-well plates in minimal essential medium 
(MEM) with 5% Fetal Bovine Serum (FBS) (GE Healthcare Life Sciences, SH30118.03), 
Penicillin/Streptomycin (Pen/Strep) (Corning, 30-002-Cl) and Glutamine (Lonza, 17-
605E). Ten-fold viral dilutions were prepared in MEM without serum. Wells were 
washed twice with 1 ml of PBS. 100 μl of each virus dilution was added to each well. 
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Plates were incubated at 37°C/5%CO2 for one hour. Overlay (2% agarose and 2x 
MEM/Bovine Serum Albumin (BSA) at 1:1 ratio) was prepared after 40 minutes of 
incubation. Following the one hour incubation period, the infection medium was removed 
and 2ml of overlay per well was added. Once agar hardened, plates were incubated 
upside down for 3 days at 37°C/5%CO2. After 3 days, agar plugs were removed with a 
spatula and plaques were stained with 1% crystal violet. The stain was removed, the wells 
were washed and the plate dried upside down on a paper towel. Plaques were counted 
visually.  
Type 3 S. pneumoniae (ATCC 6303) was used in our studies. Colony Forming 
Unit (CFU) assays were performed to confirm bacterial stock concentrations after growth 
of bacteria in Brain Heart Infusion (BHI) broth at 37°C/5%CO2 overnight. Petri dishes 
(Fisher brand, FB0875712) were filled with 25ml of BHI (BD 237500) agar (Fisher 
Bioreagent BP1423-500) and were kept at room temperature until solidified. A ten-fold 
serial dilution (10-1 to 10-6) was made with 900μl of BHI broth and 100μl of bacterial 
stock. Using a P200 micropipette, 100 microliters of each dilution was dispensed onto 
each plate (1 plate per dilution). Plates were incubated upside down at 37°C/5%CO2. The 
following day, colonies were inspected and counted visually. The dilution with colonies 
in the 30 -300 range was selected to obtain the CFU/ml.  
 
Infection schemes and Treatment 
For in vitro studies, macrophages were washed 2X with phosphate buffered saline 
(PBS), and 200 μl of Roswell Park Memorial Institute (RPMI) medium (Corning,10-
040e) was then added to each well. Multiplicity of infection (moi =#pathogens/#of cells) 
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was used to calculate the volume of pathogen stock to add (#of cells in well X MOI / 
concentration of pathogen stock). Macrophages were then mock infected, or single 
infected, either with 10 moi of PR8 or 1 moi of S. pneumoniae, or coinfected with 10 moi 
of PR8 then 3 hours later 1 moi of S. pneumoniae. After an additional hour, 200 μl RPMI 
with 20% FBS was added to all wells (Figure 2). Cell lysates and supernatants were then 
collected at 6, 12 or 24 hr time points for analysis by western blot, real-time quantitative 
polymerase chain reaction (qRT-PCR) or enzyme-linked immunosorbent assay (ELISA).  
For in vivo studies, mice were anesthetized on day 0 by intraperitoneal injection 
with 80mg/kg Ketamine and 8mg/kg Xylazine diluted in PBS. Mice were infected with 
125 PFU PR8 intranasally in a volume of 30 μl of PBS. Some mice were mock infected 
or coinfected on day 7 with 1000 CFU S. pneumoniae intranasally in a volume of 30 μl of 
PBS (171, 188). Additional mice were also singly infected with 1000 CFU S. pneumoniae 
on day 7. At all time points, mice were monitor at least daily for weight loss and mice 
were euthanized when they achieved 30% weight loss or became moribund. 
Alternatively, mice were euthanized on day 9 to collect lungs and blood for examining 
gross lung pathology, cytokine levels by ELISA, cell population by flow cytometry and 
for determining pathogen titer by CFU and PFU assays. Viral titers from homogenized 
lungs were analyzed by plaque assay using MDCK cells as previously reported (189). 
Quantification of S. pneumoniae from lung homogenates was done by making 10-fold 
serial dilutions of the lung homogenate and plating 100ml on brain heart infusion agar 
plates and incubating in a 37 ˚C incubator with 5% CO2 for 24 hr (Figure 3). 
Some groups of mice were treated after coinfection on day 7 by intraperitoneal 
injection with either clindamycin hydrochloride (60mg/kg), and/or an IL-1β neutralizing 
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antibody (Armenian Hamster IgG anti-mouse/rat IL-1β, 25 mg/kg), or an isotype control 
antibody (Armenian Hamster IgG 25 mg/kg) (BioXcell, clones BE0246 and BE0091). 
Clindamycin injections were given twice a day starting 18 hours after coinfection. 
Antibody injections were started 1 hour after coinfection and administered every other 
day. All experiments were performed at least in triplicate (Figure 4). 
 
 
Sample Analysis 
Enzyme-linked immunosorbent assay (sandwich ELISA) was used to analyze 
cytokine levels in cell culture supernatants or whole lung homogenates were analyzed 
using mouse Ready-SET-Go ELISA kits (eBioscience) for IL-1β (88-7013), IL-6 (88-
7064), or TNF-α (88-7324). Assays were performed using the manufactures 
recommendations. Microtiter plates were read at 450 nm using a BioTek ELx800 
microplate reader. 
Protein expression was analyzed through Sodium Dodecyl Sulfate Polyacrylamide 
Gel Electrophoresis (SDS-PAGE) (Fisher Bioreagens BP166-500) and Immunoblotting. 
4x SDS loading dye (glycerol, bromophenol blue, 2-beta-mercaptoethanol, Tris buffer 
and water) was added to lysates collected from in vitro infected BMDMs at different time 
points as described above (in vitro infection scheme and collection). Lysates were boiled 
at 95°C for 20 minutes, centrifuged for 5 seconds and subjected to SDS-PAGE at 100V 
for two hours. Gels were electrophoretically transferred onto polyvinylidine difluoride 
(PVDF) membranes ( GE Healthcare life Sciences,10600023) at 40V for 45 minutes. 
PVDF membranes were transferred to a container with 10 mls of 5% milk in Tris Buffer 
Saline (Fisher Bioreagents, BP152-1) + 0.05% Tween 20 (Fisher Scientific, BP337-500) 
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(TBST) for blocking the membrane. The container was placed on a shaker at room 
temperature for one hour. Milk was discarded and 10 mls of protein specific primary 
antibodies diluted in 5% milk in TBST was added to the container (Table 1). The 
container was covered and kept under 4°C refrigeration overnight. The following day the 
diluted antibody was saved and the membranes were washed 3 times with 10 mls of 
TBST. Membranes were incubated at room temperature for 5 minutes on the shaker for 
every wash. After the last wash was discarded, protein specific secondary antibodies 
diluted in 5% milk was added to the container (Table 1). The container was placed on a 
shaker at room temperature for 45 minutes. After incubation, the diluted antibody was 
saved and the membranes were washed 4 times with 10 ml of TBST. Membranes were 
incubated at room temperature for 5 minutes on the shaker for every wash. The last wash 
was not discarded, instead the membranes were transferred to another container and were 
finally treated with SuperSignal West Femto Maximum Sensitivity Substrate 
(ThermoScientific 34096). Bands were visualized using Azure biosystems C300 imaging 
system. 
Viral titers from homogenized lungs were analyzed by using MDCK cells through 
a plaque assay, detailed procedure can be found above (preparation of viral and bacterial 
stocks section). Plaque forming units were identify visually. Quantification of S. 
pneumoniae colony counts was done through CFU assay, detailed procedure can be 
found above (organism of interest section). Identification of colonies was done by visual 
inspection. 
Flow Cytometry was used to analyzed cell population in in vivo experiments. 
Lungs were collected on day 9 post-infection.  Lungs were homogenized by passing them 
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through a 70μm cell strainer using RPMI and the back of a syringe. Homogenate was 
centrifuged for 7 minutes at 400g, supernatant was removed, and pellet was resuspended 
in 5 mls of RBC lysis buffer and 5 ml RPMI. Samples were centrifuged for 7 minutes at 
400 g. Supernatant was removed and pellet was resuspended in 5 mls of 37.5% percoll at 
room temperature and centrifuged for 20 minutes at 1000g. All but 500μl of percoll was 
removed and 2mls of PBS were added. Samples were centrifuged at 400 g for 7 minutes, 
supernatant was removed and samples were stained with fluorescent antibodies (Table 2). 
Samples were run on the flow cytometer. Data was analyzed using FCS Express. Material 
were obtained from Life Technologies. 
Histopathology was used in this study to examine diseased mice lungs. C57Bl/6 
and transgenic mice were euthanized on day 9, two days after coinfection, to collect their 
lungs. Uninfected lungs from two mice were obtained at the same time as controls. Lungs 
were kept in formalin buffer. Fixed lungs were placed in individual cassettes and were 
processed in a Leica tissue processor on a 10-hour run to make cells transparent and able 
to be stained. Each cassette containing the processed tissue was then embedded in a block 
of paraffin. A Leica microtome StatLab low profile blades was used to cut the blocks. 
These were then placed onto Apex charged slides, usually with 2 or more sections per 
slide. Slides were then stained with hematoxylin and eosin. Permount toluene-based 
mounting media was used to cover slip the slides. Slides were examined by pathologist 
Dr.Gilbert. Each lung was scored using a system based on 27 characteristics (Table 3). 
Slides were imaged on an Olympus C23 microscope with an Amscope 5 mega-pixel 
digital microscope camera. 
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Real-time qPCR was used in this study to detect the expression of different 
cytokine genes.  Extraction of total mRNA was done by using TRIZOL 
(Invitrogen,AM97381). mRNA was then reverse-transcribed into cDNA using a high 
capacity cDNA reverse transcription kit (Applied Biosystems, 4368814 ). cDNA samples 
were analyzed by  real-time quantitative PCR (RT-qPCR) using DyNAmo HS SYBR 
Green qPCR Kits (Thermo Scientific, F,410L) and relative values normalized to β-actin 
control (see Table 4 for primer sequences). 
 
Statistical Analysis 
For in vitro experiments and in vivo cytokine production, one-way ANOVA with 
Tukey’s post hoc analysis was performed using PRISM6. For weight loss during in vivo 
experiments, two-way ANOVA with Dunnett's post hoc analysis was performed using 
PRISM6. For survival in vivo experiments, survival analysis was performed using the 
Wilcoxon test using PRISM6. For the histological score, a one-way ANOVA with the 
Kruskal-Wallis test was performed. A p value <0.05 was considered statistically 
significant for all tests. 
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RESULTS 
 
 
          To determine mechanisms by which the coinfection of IAV and S. pneumoniae 
affect IL-1β and other cytokines, bone marrow derived macrophages (BMDM) were 
infected with influenza A/PR/8/34 H1N1 (PR8) and S. pneumoniae ATCC 6303 type 3 
strain (S.p.) either alone or 3 h apart (See Figure 2 for infection scheme).  
 
Increased Production of Cytokine in vitro During Coinfection 
Cytokine levels in culture supernatants were compared to uninfected controls after 
24 h. A significant increase in the level of IL-1β was seen during coinfection of IAV and 
S.p. compared to untreated or single infected samples (Figure 5A). Significant increases 
in the production of IL-6, and TNF-α in coinfected samples were also observed (Figure 5 
B-D).  
Enhanced Production of IL-1β can Result from Bacterial Overgrowth. 
Previous reports show that IAV and S.p. coinfection results in increased bacterial growth 
(73, 135, 171, 190). To determine if S.p. growth affects cytokine production during 
coinfection in vitro, BMDMs were infected with PR8 and then live or heat-killed S.p. was 
added to wells either alone or 3 h apart from PR8. The heat-killed bacteria should only be 
able to initially activate PRRs by peptidoglycan detection, yet since it is dead, additional 
bacterial growth should not occur. Testing different amounts of bacteria could have been 
another way to examine the effect of bacterial numbers on IL-1β levels, yet since we 
were not interested in the specific amount required for IL-1β production, we did not go 
this path. Samples collected after 24 h indicate the production of IL-1β, TNF-α and IL-6 
levels were impacted negatively by heat killing the bacteria. However, even when 
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macrophages were coinfected with PR8 and heat killed S.p., there was still an increase in 
IL-1β over single infections alone. Thus, bacterial overgrowth can only partially be 
responsible for enhance cytokine production (Figure 6 A-C).   
            Overproduction of IL-1β is not Associated with Enhanced Inflammasome 
Activation. IL-1β is produced as an inactive precursor that must be cleaved to be 
functionally active. Enhanced IL-1β observed during coinfection could, therefore, result 
from increased expression of pro- IL-1β or from the enhanced activation of IL-1β by 
caspase-1 in the inflammasome. Inflammasome activation was first examined by 
generating BMDM from WT mice or mice deficient in inflammasome components Asc-/-, 
Casp1-/-, Nlrp3-/- or Aim2-/-. Macrophages were then infected with PR8 and S.p. singly or 
coinfected 3 hours apart. In cells lacking the inflammasome components caspase-1, ASC, 
or NLRP3, it was observed through ELISA that IL-1β levels significantly decreased 
compared to WT (Figure 7A). However, BMDM deficient in AIM2 did not show a 
significant difference compared to WT cells (Figure 7A). The inflammasome is clearly 
required for pro-IL-1β activation during single infections or coinfection, but it is not clear 
if there is enhanced Caspase-1 activation in coinfections. To answer this question, the 
same infection scheme was used and western blots were performed to check for caspase-
1 activation. However, active caspase-1 (caspase-1 p20) levels were similar regardless of 
whether BMDM were singly infected or coinfected (Figure 7B). This suggests that 
enhance IL-1β is not due to more pro-IL-1β being activated by caspase-1. 
            Overproduction of Pro-IL-1β is Associated with Enhanced NF-κB Activation. 
As enhanced Caspase-1 activation which would result in more pro- IL-1β being cleaved 
is not evident during coinfection, we examined pro-IL-1β expression to determine if 
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increased signaling through PRRs during coinfection enhances the activation of signals 
that will initiate the production of pro-IL-1 β. BMDMs were infected with PR8 and S.p. 
alone or coinfected 3 h apart. Samples were collected at 6, 12 or 24 h after initial 
infection and examined by western blot for pro-IL-1β expression. It was observed that 
pro-IL-1β expression was enhanced during coinfection more than singly infected samples 
(Figure 8A). The transcription factor NF-κB initiates transcription of the gene responsible 
for production of pro-IL-1β (191, 192). To verify that NF-κB is important during 
coinfection, BMDMs were infected and samples collected at 6, 12, and 24 h after initial 
infection. Western blots of phosphorylated-IκBα (p-IκBα) and total IκBα were performed 
to determine activation of the NF-κB pathway. In agreement with increased pro-IL-1β 
expression, p-IκBα levels were higher during coinfection, indicating enhanced NF-κB 
activation, which would results in the elevated production of pro-IL-1β (Figure 8 A). 
Finally, RNA was isolated from singly and coinfected BMDM at 6, 12, and 24 h after 
initial infection and performed qRT-PCR. It was observed that IL-1β, TNF-α and IL-6 
mRNA were all expressed at higher levels in coinfected samples (Figure 8 B-D).  
           Examination of Signaling Pathways Necessary for IL-1β Production in vitro. 
As enhanced NF-κB activation appears to be responsible for more IL-1β, we next 
examined the signaling pathways upstream of NF-κB (Figure 1). Various TLRs, NLRs 
and RLRs can facilitate NF-κB activation through adaptor proteins. I hypothesized that 
during coinfection, the NOD2-RIPK2 pathway could respond to S.p. peptidoglycan 
fragment muramyl di-peptide (MDP), RIG-I-MAVS pathways would respond to IAV 
RNA, and TLRs 2, 3, 7 and 9 could respond to their various ligands and activate TRIF or 
MYD88. Each of these pathways has the potential to activate NF-κB and subsequently 
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enhance pro-IL-1β expression. Thus to determine the pathways involved in pro-IL-1β 
expression during coinfection, BMDMs deficient in Ripk2-/-, Trif-/-, Myd88-/- or Mavs-/- 
were infected and the effect on IL-1β production in culture supernatants 24 hours after 
initial infection was examined. It was observed that only coinfected Myd88-/- BMDM had 
significantly reduced IL-1β compared to WT BMDM (Figure 9A). BMDM from Tlr2-/- or 
Tlr7-/- mice were then examined, and it was found that only Tlr2-/- BMDM had 
significantly impaired IL-1β production during coinfection compared to WT cells (Figure 
9B). As the TLR2-MYD88 signaling axis was most responsible for the increased 
expression of IL-1β, RNA from singly and coinfected BMDM obtained from WT mice at 
6, 12, and 24 h after initial infection was isolated and qRT-PCR was performed. 
Interestingly, infected cells with either IAV, S.p. or coinfected showed enhanced 
expression of MYD88 (Figure 9C). Thus, it was hypothesized that MYD88 was 
important because at the time of coinfection, after 3 hours of initial IAV stimulation, 
there was more MYD88 available for S.p. to activate and potentiate a signal. To further 
examine this enhanced signaling capacity during coinfection, BMDMs were infected with 
the same amount of the ligand peptidoglycan (PGN) either at the same time as IAV or 3 
hours apart like previously performed with S.p.; elevated levels of IL-1β were seen when 
the second signal was given after 3 hours of initial IAV infection (Figure 9D). Thus, time 
in between the coinfection results in an increase of IL-1β likely due to more MYD88 
being available for signaling. 
 
Pathways Regulating IL-1β in vivo During Coinfection 
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We next examined the effects of coinfection in vivo on cytokine production and 
inflammation. Mice were infected with a non-lethal dose of 125 PFU of PR8 intranasally 
on day 0 and then mock infected or coinfected with a non-lethal dose of 1000 CFU S.p. 
intranasally on day 7. Another group of mice were singly infected with S.p. on day 7. On 
day 9 after the initial flu infection (day 2 post-coinfection or S.p. infection), mice were 
euthanized and lungs were collected for further analysis. Similar to infection in BMDM, 
lungs from coinfected mice showed increased production of IL-1β, TNF-α and IL-6 
during coinfection in WT mice compared to PR8 or S.p. single infection (Figure 10 A-C). 
Mice deficient in either Nlrp3 or Myd88 showed significantly decreased production of 
IL-1β and Myd88-/- mice also showed significantly lower TNF-α levels compared to WT 
coinfected mice. Intriguingly, no significant differences were seen in IL-6 levels in any of 
the transgenic mice compared to WT mice (Figure 10 A-C).  
Morbidity and Mortality. To determine the effects of cytokine production 
dependent on NLRP3 and MYD88 on morbidity and mortality during coinfection, mice 
were infected as before and monitored for survival until day 14 after initial PR8 infection 
(day 7 post-coinfection). Although all genotypes of mice lost weight during infection 
with PR8, Myd88-/- mice consistently exhibited the highest weight loss (Figure 11 A). As 
previously reported, Aim2-/- mice lost significantly less weight during PR8 infection 
(Figure 11A) (193). However, no mice succumbed to PR8 infection alone due to the low 
infectious dose. Single infection with S.p. had little effect on weight loss due to the low 
infectious dose (Figure 11C). However, significant mortality was observed in Myd88-/- 
mice infected with S.p. alone (Figures 11D). During coinfection, Myd88-/- mice were 
more susceptible than WT mice (Figure 11 E-F). Aim2-/- mice displayed a similar 
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morbidity and mortality (Figure 11E-F). Finally, although Nlrp3-/- mice had similar 
mortality compared WT mice, they recovered weight faster than any other genotype of 
mice (Figure 11E-F).  
             Lung Pathology and Viral and Bacterial Titers. To understand the accelerated 
weight gain seen in Nlrp3-/- mice, we further examined lung pathology and viral and 
bacterial titers during coinfection. By day 9 (day 2 post-coinfection) PR8 was almost 
completely cleared from the lungs of WT, Myd88-/-, Nlrp3-/- and Aim2-/- mice and we 
observed no significant differences in viral titers (Figure 12A). S.p. titers were still high 
on day 9 (day 2 post-coinfection), but there was also no significant difference among the 
WT and the Myd88-/-, Nlrp3-/- and Aim2-/- mice. The bacterial titers in the lungs of Myd88-
/- mice were non-significantly higher than the Nlrp3-/- mice (Figure 12B). Bacterial titers 
in the blood of coinfected mice euthanized on day 9 were also collected, and Myd88-/- 
mice had less bacterial titers present in the blood. Histopathology examination showed 
that Myd88-/- mice had less lung damage during coinfection than WT mice, yet when total 
histological scores were compared among the genotype groups, no significance was 
found (Figure 13 A-B). I thus conclude that decreased activation of the NLRP3 
inflammasome, improves recovery from coinfection, perhaps by improving bacterial 
clearance or by improving malaise. In contrast, Myd88-/- mice have higher bacterial titers 
in the lungs compared to the Nlrp3-/- mice, which could explain why these mice succumb 
to the infection. The lower bacterial titers in the blood of Myd88-/- mice may also suggest 
the dissemination of bacteria to other organs at an earlier time after coinfection. Though 
this remains to be determined. 
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            Immune Cell Infiltration into the Lungs During Single or Coinfection. To 
have a further understanding of the underlying mechanism behind the increased amount 
of IL-1β in vivo during coinfection, the immune cell populations during the different 
infection schemes were analyzed through flow cytometry. Macrophage, neutrophil, 
dendritic cells and lymphocytes populations were analyzed in WT and knockout mouse 
lungs, either single or coinfected, collected on day 9 (day 2 post-coinfection). A 
significant increase of neutrophils was seen in the Myd88 deficient mice compared to WT 
(Figure 14A). A significant increase was also seen in the CD4 and CD8 populations in 
the Myd88 deficient mice compared to WT (Figure 14B). However, these findings do not 
agree with the histology reports where infiltrates of neutrophils and lymphocytes were 
lower in the Myd88 deficient mice, yet the difference between WT and Myd88 deficient 
mice was not significant in the histology samples (Figure 13B). As yet, it is not clear why 
there is a discrepancy between the histology and flow cytometry sampling methods. 
 
Effects of Individual or Combination Treatment with IL-1β Neutralizing Antibody 
and Clindamycin in Mice 
          To address the therapeutic potential of inhibiting IL-1β, WT mice were infected 
and treated them with an IL-1β neutralizing antibody beginning 1 h after coinfection. It 
was also considered that dramatic neutralization of IL-1β alone could impact viral or 
bacterial clearance. Thus, additional mice were treated with clindamycin or a 
combination of IL-1β neutralizing antibody and clindamycin, where clindamycin 
treatment was initiated 12 h post-coinfection. As a control, a fourth group of mice was 
injected with an Armenian Hamster IgG antibody isotype control (mock treatment). All 
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mice were then either monitored for 7 d for weight loss and survival or their lungs were 
collected on day 9 (2 d post-coinfection) to check cytokine levels and viral and bacterial 
titers in the lungs (see Figure 4 for timeline). The IL-1β neutralizing antibody, the 
clindamycin, and the combination of both treatments significantly decreased the levels of 
IL-1β present in the lungs during coinfection (Figure 15 A). The levels of IL-6 were also 
reduced, but the levels of TNF-α in the lungs were not (Figure 15 B-C). Treatment with 
clindamycin alone significantly improved mortality but not weight loss (Figure 16A-B). 
Treatment with IL-1β neutralizing antibody alone resulted in improved weight loss, but 
no difference in mortality compared to mock treated mice (Figure 16 A-B). Importantly, 
combination treatment with clindamycin and IL-1β neutralizing antibody resulted in 
improved weight loss and mortality (Figure 16A-B). To better understand these findings, 
the viral and bacterial titers in the lungs of mice on day 2 post-coinfection were also 
examined. There were no significant differences in viral titers between mock, the 
clindamycin, IL-1β  neutralizing antibody, and the combination treatment groups (Figure 
16C). It was found that clindamycin treatment significantly decreased bacterial numbers, 
but IL-1β neutralizing antibody did not significantly affect bacterial numbers (Figure 
16D).  No significant difference was found in the blood of coinfected mice among the 
treatment groups (Figure 16 E). To have a further understanding of the underlying 
mechanism behind the effects on morbidity and mortality among the different treatments 
lung histopathology and the cell population during the different drug treatments in 
coinfected WT mice was analyzed through hematoxylin & eosin (H&E) staining and flow 
cytometry. No significant difference among the treatments and the histological 
characteristic was observed (Figure 17A-B). No significant difference among the 
 37 
treatment and the cell population was detected (Figure 18A-B). I thus conclude that 
combination treatment with IL-1β neutralizing antibody and clindamycin does not 
intervene with cell population or histopathology, at least at the time point we examined 
(Day 9). Combination treatment does have therapeutic benefit by inhibiting bacterial 
growth and preventing overt cytokine production resulting in improved morbidity and 
mortality associated with coinfections.  
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DISCUSSION 
 
            Inflammation allows a host to fight infection by facilitating the production, 
activation, and transportation of cytokines, receptors, and inflammatory cells. When 
improperly regulated or overly activated, inflammation can have detrimental results. The 
coinfection of IAV and S. pneumoniae has been linked to increased death rates during 
pandemic outbreaks, such as the 1918 “Spanish Flu”, where pneumococcus was found in 
samples collected from infected individuals (9-12). Coinfections also occur during 
seasonal influenza epidemics to varying degrees (186, 194). Previous reports show that 
pro-inflammatory cytokines, such as TNF-α, IL-6, and type I interferons increase during 
coinfection; some displaying a detrimental effect and others a protective effect (131, 
195). Thus, an improved understanding of the role for various cytokines and immune 
cells during coinfection is needed to understand how to treat this disease.  
          The role for IL-1β and the function of various inflammasomes in activating IL-1β 
have been examined in infectious disease susceptibility, inflammatory disorders, and 
cancer progression (196-199). However, the specific role played by IL-1β and the 
inflammasome during the coinfection of IAV and S. pneumoniae has not previously been 
studied. Through in vivo and in vitro experimentation using bone marrow derived 
macrophages and transgenic mice, I have examined the importance of IL-1β in this 
setting. To this end, I have examined both the host response to the pathogen as well as the 
effect of pathogen growth on IL-1β production (Figure 19). One possible explanation for 
more IL-1β is that coinfection results in an outgrowth of S. pneumoniae. However, our 
findings show that increased IL-1β levels during coinfection occur even if heat killed 
bacteria is used in combination with IAV. If dead bacteria in combination with IAV can 
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still cause enhanced IL-1β production, then bacterial outgrowth cannot fully explain the 
increased IL-1β observed during coinfection. Instead, this augmentation of IL-1β results 
from the overproduction of the precursor of IL-1β (pro-IL-1β), and overactivation of the 
transcription factor NF-κB by upstream pattern recognition receptors and the adaptor 
protein MYD88. Importantly, the initial infection of cells with IAV enhanced the 
expression of MYD88, which is associated with a stronger signal during the secondary 
bacterial infection with S. pneumoniae. Furthermore, we show that the NLRP3 
inflammasome is important for the activation of IL-1β, but inflammasome activation 
itself is not elevated during coinfection. My data also implicate other inflammasomes or 
pathways involved in IL-1β production in vivo, as Nlrp3 deletion only partially affected 
IL-1β production. One likely hypothesis is that a combination of NLRP3 and AIM2 
contributes to inflammasome activation in vivo. Although Nlrp3-/- mice had only a partial 
decrease in IL-1β levels, I did observe improved weight loss in these mice compared to 
WT mice that survived infection. To elucidate why these mice regain their weight, 
bacterial titers were analyzed.  After 48 hours of a coinfection with a type 3 S. 
pneumoniae strain, the bacterial load in the lungs and blood of Nlrp3-/- mice decreased 
compared to WT mice, yet they were not significantly different. Previous studies with 
Nlrp3-/- mice single infected with 5 x 104 CFU of serotype 3 S. pneumoniae strain (6303) 
showed that six hours after infection bacterial numbers increased compared to WT, yet 
after 24 and 48 hours that bacterial load decreased improving morbidity. In WT mice 
after 24 and 48 hours, the bacteria disseminated to the blood and other organs such as the 
spleen, but not in Nlrp3-/- mice (119). On my experiment on day 9, all the genotypes 
started gaining weight back. On day 12 the Nlrp3-/- mice begun to gain more weight than 
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the WT, this could be due to the bacteria going back to normal levels resulting in a 
decrease in activation of pro-IL-1β by the AIM2 inflammasome. This trend is not seen in 
the Aim2-/- mice 48 hrs after infection probably due to the activation of the NLRP3 
inflammasome by the accumulation of damage already created until that point from the 
coinfection. This would also explain why elevated levels of IL-1β are seen in the Aim2-/- 
mice. Overall, these data show that 48 hours after coinfection, enhanced IL-1β is 
responsible for prolonged or overt inflammation but does not significantly affect 
pathogen burden.  
         Although Myd88-/- mice displayed decreased levels of IL-1β, this adaptor protein is 
involved in a variety of signaling pathways including most TLRs and the IL-1 receptor 
family. Therefore, Myd88-deficient mice are severely immunocompromised and, when 
coinfected, demonstrate increased mortality due to systemic complications (200). Myd88-
deficient mice also show a non-significant difference of increased bacterial titers in the 
lung compared to Nlrp3-/- mice and a significantly different decrease in the bacterial titers 
present in the blood. This suggest that bacterial burden in the lungs could be one reason 
why the Myd88-/- mice show increase mortality. Although nonsignificant, the Myd88-
deficient mice had a trend toward less lung damage compared to WT and the other 
genotypes. This could be due to decreased transcriptional activation, since most of the 
TLRs signal through MYD88, resulting in less production of pro-IL1β, less Caspase-1 
activation and less cell death. These mice also showed an increase of IL-6 which can 
have an anti-inflammatory role in the immune system, this could cause the pro-
inflammatory immune response against the bacteria not to begin on time after the co-
infection resulting in increased mortality. This increase could also suggest that other anti-
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inflammatory cytokines such as IL-10, which is known to act through MYD88-dependent 
signaling pathways (201), could be playing a role. In addition, the Myd88-/- mice showed 
an increase in neutrophils, CD4 T cells and CD8 T cells. The reason for this is not clear, 
but perhaps less immune signaling during IAV infections means that the immune 
response to S. pneumoniae can proceed more normally. However, this is only speculation 
and needs further examination. The neutrophils present could also not be functioning 
correctly, be undergoing apoptosis or still be immature. A variety of subsets of T cells 
could be categorized as CD4 T cells and some of these subsets could be playing a role in 
the decrease survival of the Myd88-/- mice, but this would again require further 
evaluation. Some of these subsets might also be present but not active. It has been shown 
that IAV induces IL-10 production, which can inhibit the activation of a type of cell 
called an invariant natural killer cells (iNKT) which usually have protective effects 
against this coinfection yet can produce lung damage. Mice missing these cells have 
increased mortality around 48 hours after coinfection (202). My findings agree with 
previous reports that Myd88-deficiency does not protect mice infected with the type 3 
strain of S. pneumoniae (119). Overall, my findings suggest that a tightly regulated, not 
excessive, but sufficient amount of inflammation is necessary to have a proper immune 
response against this coinfection. 
         After understanding the importance of IL-1β during this coinfection, its therapeutic 
relevance in mice was studied. In the clinical setting, patients are usually treated with an 
antiviral, an antibiotic or steroid. Several studies report that steroid treatment does not 
improve morbidity and mortality during coinfection in human patients (183, 184). Beta-
lactam antibiotics increase inflammation by releasing more bacterial ligands, potentially 
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worsening the condition in severe cases (182). Antivirals may improve survival in mice, 
particularly when combined with an antibiotic (135, 181, 203). The antibiotic 
clindamycin, which inhibits bacterial growth and reduces inflammation as a secondary 
effect, increases survival rates in mice during coinfection (135, 182). As I explored 
treatment options for coinfection, I used clindamycin in combination with IL-1β 
neutralizing antibody. Mice treated with IL-1β neutralizing antibody alone in my 
experiments showed improved weight loss, but this treatment alone did not improve 
overall survival. Treating the bacterial infection by using clindamycin and further 
controlling inflammation with the IL-1β neutralizing antibody in my experiments resulted 
in decreased weight loss and improved mortality in mice. Thus, IL-1β neutralization may 
have a place as an adjunct treatment to improve recovery time in cases of influenza A 
virus and S. pneumoniae coinfection.  
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Table 1. Western blot antibodies. Membrane was incubated with primary antibody 
overnight. Secondary antibody was added the following day. Antibodies were selected 
depending on the protein of interest. 
 
 
 
anti-β-Actin (D6A8) anti-rabbit HRP secondary 
antibody 
Cell signaling technologies 
IL-1β (D3H1Z) anti-rabbit HRP secondary 
antibody 
Cell signaling technologies 
phosphorylated-
IκBα,Ser32 (14D4) 
anti-rabbit HRP secondary 
antibody 
Cell signaling technologies 
IκBα antibody 
(9242) 
anti-rabbit HRP secondary 
antibody 
Cell signaling technologies 
Anti-caspase-1(p20 
mouse) 
anti-mouse HRP secondary 
antibody 
Adipogene, AG-20B-0042-
C100 
 
 
 
 
 
 
 
 
 
 
 
 Western Blot Antibodies  
Primary antibody Secondary Antibody Purchased from 
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Table 2. Fluorescent antibodies. The fluorophores detect specific cell receptors. These 
receptors represent a cell population. 
 
         
      Fluorescent antibodies 
  
 
Chanel 
 
Fluorophore 
 
Monocyte 
Receptor 
 
Represents 
 
Lymphocyte 
Receptor 
 
Represents 
FL-1 FITC CD11c 
Dendritic 
cells 
CD4 CD4 T cells 
FL-2 PE GR1 Neutrophils CD8 CD8 T cells 
FL-3 PerCP TCR-β T cells TCR-β T cells 
FL-4 APC CD11b Macrophages CD19 B cells 
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Table 3. Histological Scoring. Lungs collected from infected mice were analyzed by a 
pathologist and scored based on different characteristics. 
 
 
 
Histological Score 
 
Score 
infiltrate of 
neutrophils 
infiltrate of 
lymphocytes  airways Architecture 
 
0 
No significant 
abnormality. 
No significant 
abnormality. 
unremarkable 
airways 
intact alveolar 
architecture 
1 
Very patchy 
moderate  
Very patchy 
moderate  early plugging mostly intact  
2 
Mild patchy 
infiltrate 
Mild patchy 
infiltrate plugging  
inflamed 
airways 
3 
Mild fairly 
diffuse 
Mild fairly 
diffuse 
early 
obliteration 
architectural 
breakdown  
4 Patchy moderate  Patchy moderate  
diffuse 
obliteration of 
airways 
severe 
architectural 
breakdown 
5 Moderate mixed Moderate mixed   
 tissue mostly 
lost. 
6 Marked infiltrate Marked infiltrate     
          
  
YES (+1) / NO 
(0)       
Alveolar 
hemorrhage         
Necrosis         
    
Overall  Score  
____/27 
 68 
Table 4. Real Time-qPCR primer sequences. Forward and reverse primers were added to a 
master mix depending on the mRNA of interest.  
 
Real Time-qPCR primer sequences 
Primer Forward Reverse 
β-Actin  
FW 5’- GGC TGT ATT CCC CTC CAT CG-
3’  
Rev 5’-CCA GTT GTT AAC 
AAT GCC ATG T-3’ 
IL-1β 
 FW 5’ GAC CTT CCA GGA TGA GGA CA 
-3’ 
Rev 5’ AGC TCA TAT GGG 
TCC GAC AG-3’ 
 TNF-α 
 FW 5’-CAT CTT CTC AAA ATT CGA GTG 
ACA A- 3’ 
Rev 5’-TGG GAG TAG ACA 
AGG TAC AAC CC-3’ 
 IL-6 
 FW 5’- TCC AGT TGC CTT CTT GGG AC 
-3’ 
Rev 5’- GTA CTC CAG AAG 
ACC AGA GG -3’ 
MYD88  FW 5’ –ATC CGA GAG CTG GAA ACG-3’ 
Rev 5’ GCA AGG GTT GGT 
ATA ATC-3’ 
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Figure 1.  Proposed signaling pathway. A) Proposed signaling pathway of the coinfection 
with IAV and S. pneumoniae B) NF-κB activation. C) ISGF3 activation. 
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Figure 2. In vitro infection scheme. To analyze the proposed signaling pathways we 
obtained bone marrow from genetically modified mice which are missing a gene 
important to the pathway mentioned previously. We harvested bone marrow from these 
mice and made macrophages, then we plated these macrophages and infected them with 
either influenza, S. pneumoniae or both. Finally, we collected the samples usually after 
24 hrs and analyzed different proteins and cytokines in our proposed pathway using 
western blotting and ELISA. 
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Figure 3. In vivo infection scheme. WT and transgenic mice were anaesthetized and 
infected with one of the three indicated infection schemes intranasally and monitored for 
weight loss and survival or euthanized and lung samples collected on the indicated day 
post initial infection. 
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Figure 4. Drug treatment scheme.  WT mice were infected and treated with clindamycin 
or IL-1β neutralizing antibody (IL-1β neut. Ab) or co-treated at the indicated times. Mice 
were monitored for weight loss and survival or euthanized and lung samples collected on 
the indicated day post initial infection. 
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Figure 5. Increased production of cytokine in vitro during coinfection. ELISA was ran on 
samples collected from BMDMs infected with one of the previously stated infection 
schemes. (A-C) IL-1β, TNF-α and IL-6 concentrations significantly increases during 
coinfection compared to the uninfected sample. Data represent 2-5 independent 
experiments using n=2 per experiment. One-way ANOVA using Tukey’s post hoc 
analysis was used for statistical comparison. ns: not significant, p values: <0.05 (*), 
<0.01 (**), <0.001 (***).  
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Figure 6. IL-1β is partially dependent on bacterial growth. (A-C).The effect of heat killed 
S. pneumoniae on cytokine production were examined by infecting BMDMs with one of 
the indicated infection schemes and performing ELISA for IL-1β, TNF-α and IL-6 on 
samples collected 24 h post-infection. Data represent 2-5 independent experiments using 
n=2 per experiment. One-way ANOVA using Tukey’s post hoc analysis was used for 
statistical comparison. ns: not significant, p values: <0.05 (*), <0.01 (**), <0.001 (***). 
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Figure 7. Overproduction of IL-1β is not associated with enhanced inflammasome 
activation. A) BMDMs from the indicated genotype of mice were infected with a single 
pathogen or coinfected. Samples collected 24 h post-infection were analyzed by ELISA. 
Two-way ANOVA using Dunnett’s post hoc analysis was used for statistical comparison. 
p values: <0.05 (*), <0.01 (**), <0.001 (***). B) Protein levels of pro-caspase-1 and 
active caspase-1p20 were measured using Western blot analysis from BMDMs infected 
as indicated for 24 h. Actin was used as a control. 
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Figure 8. Overproduction of IL-1β is NF-κB dependent. (A) Protein levels of pro-IL-1β, 
phosphorylated IκB-α and total IκB-α were measured using Western blot analysis from 
samples collected at 6, 12, or 24 h after the indicated infection. Actin was used as a 
control. (B-D) mRNA from BMDMs samples collected at 6, 12, or 24 h post-infection 
with the indicated pathogens were examined for IL-1β, IL-6, and TNF-α gene expression 
by qRT-PCR. IL-1β mRNA was normalized relative to β -Actin. One-way ANOVA 
using Tukey’s post hoc analysis was used for statistical comparison. p values: <0.05 (*), 
<0.01 (**), <0.001 (***). 
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Figure 9. MYD88 is necessary for IL-1β production in vitro. A-B) ELISA was ran on 
samples collected from BMDMs infected with one of the infection schemes. C) mRNA 
from BMDMs samples collected at 6, 12, or 24 h post-infection with the indicated 
pathogens were examined for MYD88 gene expression by qRT-PCR. MYD88 mRNA 
was normalized relative to β -Actin. D) ELISA was run on samples collected from 
BMDMs infected with one of the infection schemes using Peptidoglycan (PGN) at the 
same time during coinfection or three hours apart. One-way ANOVA using Tukey’s post 
hoc analysis was used for statistical comparison. p values: <0.05 (*), <0.01 (**), <0.001 
(***). 
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Figure 10. Increased production of IL-1β in vivo is dependent on MYD88 and NLRP3.   
(A-C) Indicated cytokine levels were examined in whole lung homogenates on day 9 post-
PR8, day 2 post-S.p. or day 2 post-coinfection. Data are representative of two experiments, 
n=5-7 mice per group per experiment. One-way ANOVA using Tukey’s post hoc analysis 
was used for statistical comparison. ns: not significant, p values: <0.05 (*), <0.01 (**), 
<0.001 (***). 
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Figure 11. Morbidity and mortality of infected transgenic mice. (A,C,E). Weight loss in 
mice infected with PR8 alone, S.p. alone, or PR8-S.p. coinfection. (B,D,F) Mortality in 
mice infected with PR8 alone, S.p. alone, or PR8-S.p. coinfection. (A-F) Data are 
combined from two to three experiments, total n is indicated. Two-way ANOVA using 
Tukey’s post hoc analysis was used for statistical comparison for weight loss and Kaplan-
Meier Survival Plot and LogRank Test for survival data. ns: not significant, p values: 
<0.05 (*), <0.01 (**), <0.001 (***). 
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Figure 12. Viral and Bacterial titers in knockout mice. (A-B) Bacterial and viral titers in 
whole lung homogenates of coinfected mice on day 2 after coinfection.  (C) Bacterial 
titers in blood of coinfected mice on day 2 after coinfection. Data are representative of 
two-three experiments, n=5-7 mice per group per experiment. One-way ANOVA using 
Tukey’s post hoc analysis was used for statistical comparison (no differences were 
statistically significant). 
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Figure 13.  Histopathology of coinfected lungs. (a) Representative lung cross-section 
stained with H&E (40X). (B) Histological score from cross- sections of coinfected mice 
lungs obtained on day 2 after coinfection stained with H&E. Data are representative of 
two-three experiments, n=5-7 mice per group per experiment. One-way ANOVA using 
Dunn post hoc analysis and the Kruskal-Wallis test was used for statistical comparison. 
(no differences were statistically significant). 
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Figure 14.  Immune cell population during infection schemes with transgenic mice. 
Coinfected lungs of 9-14 mice were homogenized and analyzed by flow cytometry. A)  
Antibodies to detect neutrophils, macrophages and dendritic cells were used. B)  B cell, 
CD4 T cell and CD8 T cell population in WT and knockout  mouse lungs were analyzed. 
One-way ANOVA using Tukey’s post hoc analysis was used for statistical comparison. 
ns: not significant, p values: <0.05 (*), <0.01 (**), <0.001 (***). 
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Figure 15. Combination treatment with clindamycin and IL-1β neutralizing antibody in 
mice. (A-C) Indicated cytokines were examined in whole lung homogenates on day 2 
post-coinfection (day 9 post-PR8) by ELISA (A-C) Data are representative of two 
experiments, n=3-7 mice per group per experiment. One-way ANOVA using Tukey’s 
post hoc analysis was used for statistical comparison. 
 84 
 
 
 
 
Figure 16. Morbidity and mortality during treatment. (A-B) Weight loss and mortality in 
WT mice coinfected and then treated with the indicated antibiotic and/or IL-1β 
neutralizing antibody. (C-D) Bacterial and viral titers in whole lung homogenates of 
coinfected mice on day 2 post-coinfection. (A-B) Data are combined from two 
experiments, total n is indicated. Two-way ANOVA using Tukey’s post hoc analysis was 
used for statistical comparison for weight loss and Kaplan-Meier Survival Plot and 
LogRank Test for survival data. ns: not significant, p values: <0.05 (*), <0.01 (**), 
<0.001 (***). (C-D) Data are representative of two experiments, n=3-7 mice per group 
per experiment. One-way ANOVA using Tukey’s post hoc analysis was used for 
statistical comparison.  
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Figure 17.  Histopathology of coinfected lungs treated with an antibiotic, a neutralizing 
antibody or combined treatment. (a) Representative lung cross-section stained with H&E 
(10X). (B) Histological score from cross- sections of coinfected mice lungs obtained after 
treatment and on day 2 after coinfection stained with H&E. Data are representative of 
two-three experiments, n=5-7 mice per group per experiment. One-way ANOVA using 
Dunn post hoc analysis and the Kruskal-Wallis test was used for statistical comparison. 
(no differences were statistically significant). 
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Figure 18. Immune cell population among drug treatments. Coinfected lungs of 9-14 
mice were homogenized and analyzed by flow cytometry. A)  Antibodies to detect 
neutrophils, macrophages and dendritic cells were used. B)  B cell, CD4 T cell and CD8 
T cell population in WT mouse lungs were analyzed. The changes of cell population 
under different treatments were studied. 
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Figure 19.  Influenza A Virus and Streptococcus pneumoniae coinfection and IL-1β 
involvement. During the coinfection of IAV and S.p. it is well known that IAV aids the 
bacteria by damaging epithelial layers, suppressing the respiratory burst of leukocytes, 
impeding bacterial clearance, depleting alveolar macrophages and dysregulating 
neutrophils. An overactive immune response results from S.p. infecting the host. This 
results in the increase production of the cytokine IL-1β. This increase is not due to 
enhanced activation of the inflammasome enzyme Caspase-1 or bacterial overgrowth. It 
is due to enhanced priming of the transcription faction NF-κB which results in elevated 
levels of pro- IL-1β. Using a neutralizing antibody to block IL-1β only helps improve 
morbidity and mortality in mice if combined with the antibiotic Clindamycin. 
 
